About: Antiviral therapy for respiratory viral infections in immunocompromised patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral therapy for respiratory viral infections in immunocompromised patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral therapy for respiratory viral infections in immunocompromised patients
Creator	Ariza-Heredia, Ella Chemaly, Roy Shahani, Lokesh
Source	Medline; PMC
abstract	Introduction: Respiratory viruses (influenza, parainfluenza, respiratory syncytial virus, coronavirus, human metapneumovirus, and rhinovirus) represent the most common causes of respiratory viral infections in immunocompromised patients. Also, these infections may be more severe in immunocompromised patients than in the general population. Early diagnosis and treatment of viral infections continue to be of paramount importance in immunocompromised patients; because once viral replication and invasive infections are evident, prognosis can be grave. Areas covered: The purpose of this review is to provide an overview of the main antiviral agents used for the treatment of respiratory viral infections in immunocompromised patients and review of the new agents in the pipeline. Expert commentary: Over the past decade, important diagnostic advances, specifically, the use of rapid molecular testing has helped close the gap between clinical scenarios and pathogen identification and enhanced early diagnosis of viral infections and understanding of the role of prolonged shedding and viral loads. Advancements in novel antiviral therapeutics with high resistance thresholds and effective immunization for preventable infections in immunocompromised patients are needed.
has issue date	2017-01-16(xsd:dateTime)
bibo:doi	10.1080/14787210.2017.1279970
bibo:pmid	28067078
has license	no-cc
sha1sum (hex)	9dba329819f979d241de14e981ca36a3f28ae7da
schema:url	https://doi.org/10.1080/14787210.2017.1279970
resource representing a document's title	Antiviral therapy for respiratory viral infections in immunocompromised patients
has PubMed Central identifier	PMC7103713
has PubMed identifier	28067078
schema:publication	Expert Rev Anti Infect Ther
resource representing a document's body	covid:9dba329819f979d241de14e981ca36a3f28ae7da#body_text
is schema:about of	named entity 'coronavirus' named entity 'therapeutics' named entity 'diagnosis' named entity 'grave' named entity 'immunocompromised' named entity 'patients' named entity 'ANTIVIRAL THERAPY' named entity 'CLOSE' named entity 'PROGNOSIS' named entity 'AREAS' named entity 'IMPORTANT' named entity 'THE GAP' named entity 'CORONAVIRUS' named entity 'EARLY DIAGNOSIS' named entity 'PROLONGED' named entity 'NOVEL' named entity 'UNDERSTANDING' named entity 'PAST' named entity 'THESE' named entity 'HUMAN METAPNEUMOVIRUS' named entity 'TO PROVIDE' named entity 'ANTIVIRAL' named entity 'GENERAL POPULATION' named entity 'RAPID' named entity 'VIRAL' named entity 'RESPIRATORY' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'PREVENTABLE' named entity 'COMMON' named entity 'TESTING' named entity 'THERAPEUTICS' named entity 'MAY BE' named entity 'RHINOVIRUS' named entity 'ENHANCED' named entity 'INFECTIONS' named entity 'DIAGNOSTIC' named entity 'TREATMENT' named entity 'OVERVIEW' named entity 'PIPELINE' named entity 'NEEDED' named entity 'CAUSES' named entity 'IDENTIFICATION' named entity 'REPRESENT' named entity 'SHEDDING' named entity 'VIRAL REPLICATION' named entity 'COVERED' named entity 'SCENARIOS' named entity 'MOLECULAR' named entity 'USED' named entity 'RESPIRATORY VIRUSES' named entity 'VIRAL INFECTIONS' named entity 'COMMENTARY' named entity 'RESPIRATORY' named entity 'PURPOSE' named entity 'MAIN' named entity 'REVIEW OF' named entity 'EFFECTIVE' named entity 'GRAVE' named entity 'DECADE' named entity 'CONTINUE' named entity 'USE OF' named entity 'ANTIVIRAL AGENTS' named entity 'PARAINFLUENZA' named entity 'THRESHOLDS' named entity 'RESPIRATORY SYNCYTIAL VIRUS' named entity 'REVIEW' named entity 'PATHOGEN' named entity 'INVASIVE' named entity 'SEVERE' named entity 'HIGH' named entity 'INTRODUCTION' named entity 'ROLE' named entity 'NEW AGENTS' named entity 'CLINICAL' named entity 'VIRAL INFECTIONS' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'IMMUNIZATION' named entity 'RESISTANCE' named entity 'continue'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software